Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWITCHMRK 1: Raltegravir vs Kaletra Switch Study
NCT00443703Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- May 2007
- Primary completion
- Apr 2009
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of raltegravir in human immunodeficiency virus infection (HIV), sponsored by Merck & Co.. Started May 2007; status: terminated.
02
Drugs
raltegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00443703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00443703.